Nexalin Technology Business Summary

Nexalin Technology, Inc. (NXL) operates as a medical technology company specializing in non-invasive neurostimulation for mental health and cognitive disorders. The company generates revenue through a multi-pronged model comprising medical device equipment sales (Gen-1 and Gen-2 consoles), international licensing fees—primarily through its joint venture in China—and recurring subscription fees from its recently launched NeuroCare® virtual clinic, an AI-driven platform for remote physician-monitored neurotherapy. Its primary business segments are centered on its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology, which targets conditions such as anxiety, insomnia, depression, and Alzheimer’s disease. In the competitive landscape of bioelectronic medicine, Nexalin competes with firms like CVRx, Inc., Hyperfine, Inc., and Envoy Medical, positioning itself as a niche leader in frequency-based, drug-free brain health interventions with a focus on deep-tissue stimulation without the need for surgical implants. The leadership team is spearheaded by Mark White, who serves as President, CEO, and CFO, bringing over 25 years of experience in medical device development and clinical operations. The company’s technical foundation rests on the work of John Patrick Claude, the Director of Engineering and R&D, who co-designed the original trans-cranial alternating current stimulation (tACS) waveform alongside Dr. Yakov Katsnelson. Clinical strategy is directed by Chief Medical Officer David Owens, M.D., a specialist in neuroradiology with extensive experience in medical software ventures. The board is chaired by Leslie Bernhard and includes Dr. Ben V. Hu, a prominent neurologist. Notable institutional backing includes positions held by Geode Capital Management and Renaissance Technologies, while significant insider ownership is maintained by Controller Marilyn Elson and former CEO Leonard Osser.